BMI1 tagged posts

BMI1, a promising Gene to Protect against Alzheimer’s disease

CREDIT: GETTY

Another step towards understanding Alzheimer’s disease has been taken at the Maisonneuve-Rosemont Hospital Research Centre. Molecular biologist Gilbert Bernier, and professor of neurosciences at Université de Montréal, has discovered a new function for the BMI1 gene, which is known to inhibit brain aging. The results of his work have just been published in Nature Communications.

In his laboratory, Bernier was able to establish that BMI1 was required to prevent the DNA of neurons from disorganizing in a particular way called G4 structures. This phenomenon occurs in the brains of people with Alzheimer’s disease, but not in healthy elderly people...

Read More

Targeting Cancer Stem Cells improves Treatment effectiveness, Prevents Metastasis

At left, head and neck squamous cell carcinoma invasive growth, and at right, cancer stem cells (shown in red) in head and neck squamous cell carcinoma. Credit: Demeng Chen and Cun-Yu Wang/UCLA

At left, head and neck squamous cell carcinoma invasive growth, and at right, cancer stem cells (shown in red) in head and neck squamous cell carcinoma. Credit: Demeng Chen and Cun-Yu Wang/UCLA

Head and neck squamous cell carcinoma is a highly invasive form of cancer and frequently spreads to the cervical lymph nodes. Currently, cisplatin is the standard therapeutic drug used for people with HNSCC. Yet, more than 50% of people who take cisplatin demonstrate resistance to the drug, and they experience a recurrence of the cancer. The 5-year survival rates remain sorely low and researchers still don’t understand the underlying mechanisms behind head and neck squamous carcinoma.

Cancer stem cells are known to be responsible for tumor formation and development; they also self-renew and tend to ...

Read More

New way to Inhibit Development of Lung Cancer

Protein BMI1 PDB 2ckl.png

BMI1

Researchers found that inhibiting protein BMI1 was able to impair tumour growth in lung cancer. The study was led by Professor Daniel Tenen, Director of CSI Singapore et al. Lung cancer is one of the deadliest cancers in the world, accounting for 30% of tumour-related deaths. Like many solid tumours, lung cancer is very heterogeneous (consisting of cancer cells which behave and respond differently) and hence there is currently no single efficient drug which is able to treat all patients.

Prof Tenen has worked on the differentiation factor C/ EBPa for several decades, demonstrating that it is an important tumour suppressor, first in acute myelogenous leukemia, and subsequently, in studies in collaboration with Dr Levantini, in lung cancer...

Read More